Description:
Empagliflozin is an orally-active inhibitor of the sodium-glucose co-transporter 2 (SGLT2) expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen.

Metformin Hydrochloride is an oral biguanide antidiabetic. Metiormin reduces elevated blood glucose concentration in patients with diabetes, but it does not increase insulin secretion. It exerts blood glucose lowering effects through the augmentation of muscular glucose uptake and utilization and reduction of increased hepatic glucose production. Metformin potentiates insulin action mainly by a_post-receptor mechanism. In this way, metformin ameliorates insulin resistance.

Indications:
Empadus^® M is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both Empagliflozin and Metiormin Hydrochloride is appropriate. Empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease.

Mode of Action:
Empagiliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, Empagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose and thereby increases urinary glucose excretion. Metformin Hydrochloride decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.

View Details